New treatment for severe lung complications from sepsis
Aerosolized Chemically Modified Tetracycline Nanoformulation for the Treatment of Acute Respiratory Distress Syndrome
This study is testing a new inhaled medication to help people with acute respiratory distress syndrome (ARDS) caused by sepsis, aiming to reduce lung inflammation and improve breathing for those at risk.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cmtx Biotech, INC. NIH-funded |
| Lab location | 1 site (Kings Park, United States) |
| Project ID | NIH-10950503 on NIH RePORTER |
What this research studies
This research focuses on developing a new aerosolized drug formulation aimed at treating acute respiratory distress syndrome (ARDS) that can occur in patients suffering from sepsis. The approach involves using a modified form of tetracycline, which is delivered directly to the lungs to target inflammation and improve respiratory function. By investigating the mechanisms of how sepsis leads to ARDS, the research aims to provide a specific treatment option for this serious condition. Patients who are at risk of developing ARDS due to sepsis may be eligible for this innovative treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults over 21 years old who are experiencing sepsis and are at risk of developing acute respiratory distress syndrome.
Not a fit: Patients who do not have sepsis or are not at risk for ARDS may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a targeted therapy for patients suffering from ARDS caused by sepsis, potentially reducing mortality rates and improving recovery outcomes.
How similar studies have performed: While there have been advancements in treating ARDS, this specific approach using aerosolized chemically modified tetracycline is novel and has not been extensively tested in clinical settings.
Where this research is happening
Kings Park, United States
- Cmtx Biotech, INC. — Kings Park, United States (Active)
Researchers
- Principal investigator: Kollisch-Singule, Michaela Christina — Cmtx Biotech, INC.
- Study coordinator: Kollisch-Singule, Michaela Christina
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.